Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) saw unusually-strong trading volume on Friday . Approximately 4,908,119 shares changed hands during mid-day trading, an increase of 304% from the previous session’s volume of 1,214,606 shares.The stock last traded at $1.30 and had previously closed at $1.20.
Separately, Roth Capital started coverage on shares of Matinas BioPharma in a research note on Monday, February 11th. They issued a “buy” rating and a $4.75 target price on the stock.
A number of institutional investors have recently modified their holdings of MTNB. D. E. Shaw & Co. Inc. bought a new stake in Matinas BioPharma during the fourth quarter worth about $26,000. Private Advisor Group LLC lifted its position in shares of Matinas BioPharma by 100.4% during the fourth quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock worth $30,000 after purchasing an additional 24,978 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Matinas BioPharma during the fourth quarter worth approximately $39,000. Northern Trust Corp lifted its position in shares of Matinas BioPharma by 18.9% during the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock worth $109,000 after purchasing an additional 29,072 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Matinas BioPharma by 325.6% during the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after purchasing an additional 103,200 shares in the last quarter.
Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Further Reading: Investing in Blue-Chip Stocks
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.